Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

22. oktober 2026 opdateret af: GlaxoSmithKline

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

800

Fase

  • Fase 3

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Buenos Aires, Argentina, 1425
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Mariano Dioca
      • Capital Federal, Argentina, C1426ANZ
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Yanina Pfluger
      • Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Guillermo Mendez
      • Ciudad Autonoma de Buenos Aire, Argentina, C1431FWO
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Julieta Grasselli
      • Ciudad autOnoma de Bueno, Argentina, C1419AHN
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Samanta Straminsky
      • San Miguel de Tucumán, Argentina, T4000IHE
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ruben Segovia
    • Victoria
      • Melbourne, Victoria, Australien, 3004
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • John Zalcberg
      • Barretos, Brasilien, 14784-400
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Arinilda Bragagnoli
      • Florianópolis, Brasilien, 88034-000
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ana Paula Stramosk
      • Natal, Brasilien, 59075-740
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Sulene Oliveira
      • Porto Alegre, Brasilien, 90020-090
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Andreas Lutz
      • Vitória, Brasilien, 29043-260
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • GLAUCIO BERTOLLO
    • Piauí
      • Teresina, Piauí, Brasilien, 64002-530
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Welligton Figueiredo
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Albiruni Abdul Razak
    • Quebec
      • Montreal, Quebec, Canada, H3A 1A1
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Jonathan Noujaim
        • Kontakt:
        • Kontakt:
      • London, Det Forenede Kongerige, SW3 6JJ
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Robin Jones
      • London, Det Forenede Kongerige, NW1 2PG
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Vasilios Karavasilis
      • Newcastle upon Tyne, Det Forenede Kongerige, NE7 7DN
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Anna Stansfeld
      • Sheffield, Det Forenede Kongerige, S10 2SJ
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Robin Young
    • Greater Manchester
      • Manchester, Greater Manchester, Det Forenede Kongerige, M20 4BX
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Alexander Lee
        • Kontakt:
        • Kontakt:
      • Helsinki, Finland, 00029
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Sari Jaamaa
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85258
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Michael Gordon
        • Kontakt:
        • Kontakt:
    • California
      • San Francisco, California, Forenede Stater, 94158
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Victoria Wang
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06510-3206
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Philippos Costa
    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20817-1802
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ralph Boccia
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64132
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Jaswinder Singh
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68130-2042
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Kirsten Leu
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Ciara Kelly
        • Kontakt:
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Juneko Grilley-Olson
        • Kontakt:
        • Kontakt:
    • Ohio
      • Canton, Ohio, Forenede Stater, 44718
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Nashat Gabrail
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37920
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Ledende efterforsker:
          • Saikrishna Gadde
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Ledende efterforsker:
          • Neeta Somaiah
        • Kontakt:
    • Washington
      • Seattle, Washington, Forenede Stater, 98109-4405
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Min Park
      • Lyon, Frankrig, 69373
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Mehdi Brahmi
        • Kontakt:
        • Kontakt:
      • Reims, Frankrig, 51100
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Olivier Bouché
      • Thessaloniki, Grækenland, 54639
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Grigorios Rallis
      • Thessaloniki, Grækenland, 55535
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ioannis Boukovinas
    • Attica
      • Chaïdári, Attica, Grækenland, 124 62
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Anastasios Kyriazoglou
    • Crete
      • Heraklion, Crete, Grækenland, 700 13
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ioannis Souglakos
      • Nijmegen, Holland, 6525GA
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ingrid Desar
    • South Holland
      • Leiden, South Holland, Holland, 2333 ZA
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Hans Gelderblom
        • Kontakt:
        • Kontakt:
      • Milan, Italien, 20133
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Elena Rosa Fumagalli
      • Milan, Italien, 20141
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Roberta Giovanna Sanfilippo
      • Palermo, Italien
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Giuseppe Badalamenti
      • Roma, Italien, 00128
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Bruno Vincenzi
        • Kontakt:
        • Kontakt:
      • Ehime, Japan, 791-0280
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Tomohiro Nishina
      • Fukuoka, Japan, 812-8582
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Eiji Oki
      • Gifu, Japan, 501-1194
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Nobuhisa Matsuhashi
      • Hokkaido, Japan, 060-8648
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Yoshito Komatsu
      • Kanagawa, Japan, 241-8515
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Hiroki Osumi
      • Osaka, Japan, 565-0871
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Yukinori Kurokawa
      • Tokyo, Japan, 104-0045
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Hidekazu Hirano
      • Tokyo, Japan, 135-8550
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Masato Ozaka
      • Toyama, Japan, 930-0194
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Takayuki Ando
      • Yamaguchi, Japan, 755-8505
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Tatsuya Ioka
      • Beijing, Kina, 100141
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Jian Li
        • Kontakt:
        • Kontakt:
      • Chengdu, Kina, 610041
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Bo Zhang
      • Guangzhou, Kina, 510060
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Haibo Qiu
      • Guangzhou, Kina, 510655
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Yanhong Deng
        • Kontakt:
        • Kontakt:
      • Guangzhou, Kina, 510080
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Xinhua Zhang
      • Hangzhou, Kina, 310016
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Yu Zheng
      • Jinan, Kina, 250021
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Lei Cong
      • Nanjing, Kina
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Hao Xu
      • Shanghai, Kina, 200000
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ye Zhou
      • Shanghai, Kina, 20001
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Ming Wang
        • Kontakt:
        • Kontakt:
      • Wuhan, Kina, 430022
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Kai-Xiong Tao
      • Zhengzhou, Kina, 450052
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Yang Fu
      • Oslo, Norge, 0379
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Kjetil Boye
      • Warsaw, Polen, 02-781
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Piotr Rutkowski
      • Genolier, Schweiz, 1272
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Michael Montemurro
      • BaracaldoVizcaya, Spanien, 48903
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Alberto Muñoz Llarena
      • Barcelona, Spanien, 8025
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Raul Teres Lleida
        • Kontakt:
        • Kontakt:
      • Madrid, Spanien, 28046
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Virginia Martinez Marin
      • Madrid, Spanien, 28034
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • María Ángeles Vaz Salgado
      • Madrid, Spanien, 28040
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Nadia Hindi Muñiz
      • Madrid, Spanien, 28041
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Aránzazu Manzano Fernández
      • Oviedo, Spanien, 33011
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Maria del Pilar Solis Hernandez
      • Seville, Spanien, 41013
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Irene Carrasco García
      • Valencia, Spanien, 46009
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Hector Augusto Aguilar Andino
      • Zaragoza, Spanien, 50009
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Javier Martínez Trufero
        • Kontakt:
        • Kontakt:
      • Uppsala, Sverige, SE-751 85
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Sharmineh Moghaddam
      • Seongnam-si Gyeonggi-do, Sydkorea, 13620
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ji-Won Kim
      • Seoul, Sydkorea, 03080
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Do-youn Oh
      • Seoul, Sydkorea, 03722
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Minkyu Jung
      • Seoul, Sydkorea, 138-736
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Min-Hee Ryu
      • Seoul, Sydkorea, 03181
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Dong-Hoe Koo
      • Suwon Kyunggi-do, Sydkorea, 16499
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Tae Hwan Kim
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Sydkorea, 06351
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Jungyong Hong
      • Changhua, Taiwan, 500
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ruo-Han TSENG
      • Taichung, Taiwan, 404
        • Rekruttering
        • GSK Investigational Site
        • Ledende efterforsker:
          • Li-Yuan Bai
        • Kontakt:
        • Kontakt:
      • Taipei, Taiwan, 10002
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Kun-Huei Yeh
      • Taipei, Taiwan, 112
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Chueh-Chuan Yen
      • Taoyuan, Taiwan, 33305
        • Rekruttering
        • GSK Investigational Site
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Chun-Nan Yeh

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).

  • Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.

  • Has not received prior systemic therapy for their metastatic and/or surgically unresectable GIST.

  • Tumor tissue must be provided to the central laboratory. Tumor tissues may be archival (preferred) or obtained from a fresh biopsy acquired for standard of care (biopsies must be collected before randomization).

  • Participants must have ≥1 target lesion (TL).

  • All participants must use adequate contraception according to local regulations throughout the study and for a specified period after the last dose of study medication (at least 30 days for velzatinib/imatinib, or 15 days for imatinib only, as applicable, or longer if local regulations specify).

  • Male participants must either be abstinent or use a male condom (with a recommendation for their female partner to use highly effective contraception). They must also refrain from donating semen.

  • Female participants must not be pregnant or breastfeeding.

    1. Those of non-childbearing potential are eligible without additional contraception.
    2. Those of childbearing potential must use an acceptable, highly effective contraceptive method and have a negative pregnancy test before starting the study. The investigator will assess their pregnancy risk.
  • Is capable of giving signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.

  • Has adequate organ function.

Exclusion Criteria:

  • Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.

  • Has any clinically significant gastrointestinal abnormalities that may alter absorption, e.g., malabsorption syndrome or major resection of the stomach and/or bowels.

  • Has had any major surgery (minor surgical procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures) within 14 days of the first dose of study treatment or participants who have not fully recovered from surgery.

  • Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was [>100 days] prior to screening, and b) the participant has no active infection(s) at the time of screening.

  • Has known allergy or hypersensitivity to velzatinib or imatinib, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

  • Has a history within 6 months prior of clinically significant or uncontrolled cardiac disease, unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure [New York Heart Association,1994], or clinically significant arrhythmia not controlled by standard of care therapy, ventricular arrhythmia, cerebrovascular accident or transient ischemic attack and uncontrolled hypertension.

  • Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed [e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases]. Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥2 weeks before randomization are not excluded from participation

  • Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, (excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy) or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.

  • Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).

  • Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

  • Has received radiotherapy within 14 days prior to first dose of study treatment.

  • Has received any live vaccine within 30 days of randomization. Vaccination against Coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.

  • Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before randomization.

  • Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of medical research before signing ICF.

  • Has a positive drug/alcohol screening assessment.

  • Has a known Human immunodeficiency virus (HIV) infection and meets at least one of the following criteria:

    1. Has documented evidence of plasma HIV-1 ribonucleic acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
    2. Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
    3. Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
    4. Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
    5. Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
    6. Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening.
  • Is pregnant or breastfeeding.

  • Is unable to adhere to the protocol, including requirements for the Follow-up Period of the study.

  • Has an alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or (for participants with documented liver metastases/tumor infiltration) has an ALT value >5x ULN

  • Has a total bilirubin value >1.5x ULN.

  • Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.

  • Evidence of chronic hepatitis B virus (HBV) infection with detectable viral load despite antiviral therapy with high resistance barrier.

  • 12-lead electrocardiogram (ECG) demonstrating mean QT interval corrected (QTc) corrected by Fridericia's formula >480msec at screening or history of long QT syndrome.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Imatinib

Imatinib will be administered

Andre navne:
  • GLIVEC / GLEEVEC
Eksperimentel: Velzatinib

Velzatinib will be administered

Andre navne:
  • GSK6042981

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
Tidsramme: Up to approximately 74 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 74 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with Treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Number of participants with TEAEs/SAEs leading to dose reductions, interruptions and treatment discontinuation
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Number of participants with clinically significant changes in vital signs, electrocardiograms, and clinical laboratory parameters
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Plasma concentration of velzatinib
Tidsramme: Up to approximately 75 months
Up to approximately 75 months
Confirmed Objective Response Rate (ORR) as assessed by BICR
Tidsramme: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response criteria.

Up to approximately 75 months
Overall survival (OS)
Tidsramme: Up to approximately 75 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 75 months
Confirmed ORR as assessed by Investigator assessment
Tidsramme: Up to approximately 75 months

Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR per response criteria.

Up to approximately 75 months
Time from initial study randomization to second disease progression or death (PFS2)
Tidsramme: Up to approximately 75 months

PFS2 is defined as the time from initial study randomization to second disease progression or death after starting the next line of treatment.

Up to approximately 75 months
PFS as assessed by Investigator assessment
Tidsramme: Up to approximately 75 months

PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first.

Up to approximately 75 months
Time to Response (TTR)
Tidsramme: Up to approximately 75 months

TTR as assessed by BICR and investigator, is defined as time from randomization until the first documented PR or CR that was subsequently confirmed.

Up to approximately 75 months
Duration of Response (DOR)
Tidsramme: Up to approximately 75 months

DOR as assessed by BICR and investigator, is defined as time from the first documented PR or CR that was subsequently confirmed until the first documented PD or death due to any cause.

Up to approximately 75 months
Time to Second Subsequent Therapy (TSST)
Tidsramme: Up to approximately 75 months

TSST is defined as the time from the date of randomization to the earliest date of second subsequent therapy or death due to any cause.

Up to approximately 75 months
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
Tidsramme: Up to approximately 75 months

The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. These include functional scales, symptom scales, global health status scale, and single item scales. Scores are averaged and transformed to 0 to 100. Higher scores indicate greater functioning, better global health status, or more severe symptoms

Up to approximately 75 months
Time to confirmed deterioration (TTCD) of EORTC QLQ-C30
Tidsramme: Up to approximately 75 months

TTCD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the Physical & Role Functioning & Global Health Status/QoL scales of the EORTC QLQ-C30.

Up to approximately 75 months
Number of participants with symptomatic AEs by severity as measured by patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Up to approximately 75 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to approximately 75 months
Number of participants with bothersome AEs/tolerability as measured by the Functional Assessment of Cancer Therapy - General (FACT-GP5)
Tidsramme: Up to approximately 75 months

The FACT GP5 is an assessment focused on the overall side effects impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5-point Likert type scale. The response scale ranges from 0 (Not at all) to 4 (Very much). Higher scores indicate a higher degree of AE bother.

Up to approximately 75 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. juli 2026

Primær færdiggørelse (Anslået)

30. august 2032

Studieafslutning (Anslået)

28. september 2032

Datoer for studieregistrering

Først indsendt

6. maj 2026

Først indsendt, der opfyldte QC-kriterier

7. maj 2026

Først opslået (Faktiske)

13. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 306293
  • 2025-524934-24 (Anden identifikator: EU CT Number)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .